Overview
Fisher & Paykel Healthcare is a global medical-device business focused on respiratory care, surgery and obstructive sleep apnoea treatment. Its shares trade at A$38.40, near the 52-week high of A$38.61, while the underlying business combines 14.00% revenue growth with a 20.30% profit margin. The central consideration is whether that growth and profitability justify a premium valuation.
Fisher & Paykel Healthcare develops medical devices and systems for acute and chronic respiratory care, surgery and obstructive sleep apnoea treatment. Its offerings span hospital and homecare settings, including respiratory support systems, humidification products, masks and CPAP devices. With revenue of A$2.3 billion and operations across North America, Europe and Asia Pacific, it has an international healthcare footprint and exposure to both clinical and home-based care.
Key facts
- Ticker
- FPH
- Exchange
- AU
- ISIN
- NZFAPE0001S2
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- Australia
- Currency
- AUD
- Price
- A$38.40
- Previous close
- A$38.08
- Day change
- +A$0.32 (+0.84%)
- Market cap
- 22.6B
- 52W low
- A$26.28
- 52W high
- A$38.61
Price and trend
Last price: A$38.40
- Price
- A$38.40
- 52W range
- A$26.28 – A$38.61
- 50-day SMA
- A$35.99
- 200-day SMA
- A$32.79
- Price vs 50D SMA
- 6.69%
- Price vs 200D SMA
- 17.10%
Valuation
- P/E
- 54.86
- PEG
- 4.47
- EPS
- 0.70
- Dividend yield
- 1.37%
- Beta
- 0.88
Fisher & Paykel Healthcare combines 14.00% revenue growth with a 20.30% profit margin, but the valuation is demanding at a P/E ratio of 54.86 and PEG ratio of 4.47. The 1.37% dividend yield is relatively modest. Investors are therefore weighing the company’s established respiratory-care business and growth against a share price that already reflects substantial expectations.
Profitability and growth
- Revenue growth
- 14.00%
- Revenue TTM
- 2.3B
- Profit margin
- 20.30%
Analyst view
Comparison uses the last price shown; targets are analyst estimates.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
- Price
- A$38.40
- Target price
- A$36.89
- Target vs last price
- -3.93% from last price
The supplied target price is A$36.89, which is 3.93% below the last price; this is a reference point rather than a forecast. It sits alongside a share price that has risen above both its 50-day and 200-day moving averages, so the technical picture is stronger than those averages alone would suggest, while the valuation remains an important consideration.
Risks
A P/E ratio of 54.86 and PEG ratio of 4.47 leave the valuation exposed if growth or profitability disappoints. The company sells internationally across hospital and homecare markets, so performance depends on demand for its products across different care settings. The share is near the top of its 52-week range, which may leave less room for setbacks to be absorbed by recent price momentum. Its 1.37% dividend yield is modest, making the investment case less reliant on income.
FAQ
What does Fisher & Paykel Healthcare do?
Fisher & Paykel Healthcare designs, manufactures and sells medical devices and systems for respiratory care, surgery and obstructive sleep apnoea treatment. Its products serve hospitals and homecare users across international markets.
How has the business been growing?
The supplied figures show revenue of A$2.3 billion and revenue growth of 14.00%. Its 20.30% profit margin also indicates that the business is generating meaningful profitability alongside that growth.
How is FPH valued and what dividend does it offer?
The shares trade at a price-to-earnings ratio of 54.86 and a PEG ratio of 4.47, pointing to a demanding valuation. The stated dividend yield is 1.37%, so the share’s profile is more centred on its healthcare business and growth than on a high yield.
*This content is aimed to provide general information only, and does not take your personal objectives, financial situation or needs into account.
